AstraZeneca PLC (AZN.ST)

1.502,00 -1,00 (-0,07%) In data: 10:33AM CEST. Mercato aperto.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 89.900

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Executive Director	4,57M	N/D	1959
Dr. Aradhana Sarin M.D.	CFO & Executive Director	2,52M	N/D	1974
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board	N/D	N/D	1970
Mr. Andrew P. Barnett	Head of Investor Relations	N/D	N/D	N/D
Mr. Jeffrey Pott	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board	N/D	N/D	N/D
Gonzalo Vina	Head of Global Media Relations	N/D	N/D	N/D
Dr. Menelas Nicolas Pangalos Ph.D.	Executive Vice-President	N/D	N/D	1967
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit	N/D	N/D	N/D
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology Research & Development	N/D	N/D	1966
Mr. Leon Wang	Executive VP of International & China President	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di AstraZeneca PLC al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 9; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.